Arcus Biosciences fell 10% after stopping its Phase 3 STAR-221 trial when independent reviewers found its domvanalimab-based combo failed to improve survival in upper GI cancers. The company will now shift focus to its HIF-2a inhibitor, casdatifan, with several data readouts and study initiations planned for 2026.